Healx: Jobs, Salaries & Tech Stack (2026)

Overview

Healx is a Cambridge company founded in 2014 that uses artificial intelligence to find treatments for rare diseases. Its knowledge graph combines biomedical literature, drug data and patient information to predict which existing compounds could be repurposed. The company advances its own pipeline of rare disease programmes into clinical trials.

News

Blog 2 months ago

Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma

Osteosarcoma is a rare, aggressive bone cancer that most often affects children, adolescents, and young adults. Patients who develop metastatic disease face particularly poor outcomes, with a five-year survival rate of less than 30% ¹. The past 40 years h

Report

News FinanzNachrichten.de 12 months ago

Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De Sciences

Healx, the AI-powered biotech company pioneering the next generation of drug discovery for rare diseases, today announced it has entered into a strategic transaction with Vuja De Sciences, a US-based

Report

Blog 12 months ago

Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De Sciences

Healx's proprietary AI platform has uncovered and prioritised therapeutic opportunities across rare diseases and is actively applied in rare and pediatric oncology. The platform is designed to generate and advance Healx's own discovery programs, making it

Report

Blog 1 year ago

Healx and SCI Ventures join forces to uncover cures for paralysis with AI-driven drug discovery

Uniting AI Innovation and Neuroregeneration Expertise This partnership combines the machine learning and drug discovery expertise of Healx with the deep scientific insight, domain expertise, and unique dataset access of SCI Ventures. Backed by leading fou

Report

Blog 1 year ago

Healx Appoints Christopher Moertel as Global Head of Clinical Development

Cambridge, UK, 6 May 2025 - Healx, a leader in AI-driven drug discovery for rare diseases, is pleased to announce the appointment of Christopher Moertel, M.D., as its new Global Head of Clinical Development. Dr. Moertel, a highly respected expert in the f

Report

Blog 1 year ago

Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of Neurofibromatosis Type 1

NF1 is a debilitating rare genetic disorder that causes tumours to form along nerves, often manifesting in childhood. It affects approximately one in 2,500 individuals worldwide and can lead to severe complications, including pain, disfigurement, and mali

Report